Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Furotriptan Succinate Extended Release Tablets

A technology of furovatriptan and succinic acid, applied in the field of drug sustained-release tablets, can solve the problems of short half-life, high relapse rate, and low oral bioavailability

Active Publication Date: 2018-03-30
CP PHARMA QINGDAO CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It overcomes the disadvantages of low oral bioavailability, short half-life and high recurrence rate of the first generation of 5-HT1B / 1D receptor agonists. Headache has a significant curative effect, and has fewer side effects than other drugs. It can be predicted that the drug has a good market prospect in China, so the industrial development of furatriptan is of great significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Furotriptan Succinate Extended Release Tablets
  • Furotriptan Succinate Extended Release Tablets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The tablet core is a skeleton tablet, including the following components, and its weight composition is:

[0024] Furotriptan succinate 200 parts

[0025] HPMC 2000 copies

[0026] Pregelatinized starch 1000 parts

[0027] Magnesium stearate 3000 parts

[0028] 125 parts of 95% ethanol solution

[0029] The coating layer comprising the coating solution of the following components is composed of:

[0030] Ethyl cellulose 100 parts

[0031] Cellulose acetate 200 parts

[0032] PEG6000 15 parts

[0033] Furotriptan succinate 8 parts

[0034] The preparation method includes the following steps: (1) Tablet core preparation: Weigh furovatriptan succinate, HPMC, and pregelatinized starch according to the prescribed amount of the tablet core and sieve them, mix them evenly, and prepare them with 95% ethanol solution as a wetting agent. into soft materials, sieve and granulate, dry the wet granules, granulate, add magnesium stearate and talcum powder and mix evenly, put ...

Embodiment 2

[0036] The tablet core is a skeleton tablet, including the following components, and its weight composition is:

[0037] Furotriptan succinate 200 parts

[0038] HPMC 2000 copies

[0039] Pregelatinized starch 1000 parts

[0040] Magnesium stearate 3000 parts

[0041] 125 parts of 95% ethanol solution

[0042] The coating layer comprising the coating solution of the following components is composed of:

[0043] Cellulose acetate 300 parts

[0044] PEG6000 15 copies

[0045] Furotriptan succinate 8 parts

[0046] The preparation method includes the following steps: (1) Tablet core preparation: Weigh furovatriptan succinate, HPMC, and pregelatinized starch according to the prescribed amount of the tablet core and sieve them, mix them evenly, and prepare them with 95% ethanol solution as a wetting agent. into soft materials, sieve and granulate, dry the wet granules, granulate, add magnesium stearate and talcum powder and mix evenly, put the above mixture into a tablet mac...

Embodiment 3

[0048] The tablet core is a skeleton tablet, including the following components, and its weight composition is:

[0049] Furotriptan succinate 200 parts

[0050] HPMC 2000 copies

[0051] Pregelatinized starch 1000 parts

[0052] Magnesium stearate 3000 parts

[0053] 125 parts of 95% ethanol solution

[0054] The coating layer comprising the coating solution of the following components is composed of:

[0055] Ethyl cellulose 300 parts

[0056] PEG6000 15 parts

[0057] Furotriptan succinate 8 parts

[0058] The preparation method includes the following steps: (1) Tablet core preparation: Weigh furovatriptan succinate, HPMC, and pregelatinized starch according to the prescribed amount of the tablet core and sieve them, mix them evenly, and prepare them with 95% ethanol solution as a wetting agent. into soft materials, sieved and granulated, after drying the wet granules, granulate, add magnesium stearate and mix evenly, put the above mixture into a tablet machine and c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a slow-release tablet comprising succinate frovatriptan. The slow-release tablet comprises a tablet core and a coating, wherein the tablet core adopts a matrix tablet, and comprises succinate frovatriptan, hydroxypropyl methylcellulose, pregelatinized starch, magnesium stearate, talcum powder, and a 95% ethanol solution; the coating comprises a slow-release coating material, polyethylene glycol and succinate frovatriptan. The slow-release tablet has the advantages that the administration number of times is reduced, the compliance of a patient is improved, and the effective blood concentration is kept for a relatively long time.

Description

technical field [0001] The invention relates to a drug slow-release tablet containing furovatriptan succinate, which belongs to the technical field of medicine. The invention provides a tablet which is safe and effective, durable in efficacy, stable in quality, low in cost, convenient in administration, strong in patient compliance and capable of treating migraine. Background technique [0002] Furotriptan succinate, Chinese chemical name: R-(+)3-methylamino-6-carbonamide-1,2,3,4-tetrahydrocarbazole monosuccinate monohydrate, the structural formula is as follows: [0003] [0004] Molecular formula: C14H17N3O C4H6O4 H2O [0005] Molecular weight: 379.4 [0006] Furotriptan was developed by Ireland's Elan Pharm acutieallne, and was approved by the US FDA in November 2001 in the form of its succinate (1:1) for the acute treatment of migraine with or without aura. Frova. At present, this product is not registered for sale in China. [0007] Furotriptan is a new type of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/36A61K31/403A61K47/38A61P25/06
Inventor 王明刚陈阳生任莉孙桂玉翟翠云刘晓霞汪泓
Owner CP PHARMA QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com